Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Matrix metallopeptidase 14 (MMP14) mRNA 3'-untranslated region (3'-UTR) is a key regulatory element that controls the expression of the MT1-MMP protein, a membrane-bound protease vital for extracellular matrix remodeling and cell signaling (UniProt: P50281). This region contains specific sequences recognized by various microRNAs (miRNAs), such as miR-181a-5p and miR-584, which act as post-transcriptional suppressors by inducing mRNA degradation or blocking translation (PubMed: 26066740). In pathological states, particularly in invasive cancers, the loss of miRNA-mediated control at this 3'-UTR often leads to the overexpression of MMP14 (PubMed: 24333729). Such overexpression facilitates tumor cell invasion, metastasis, and angiogenesis by degrading the basement membrane and activating other pro-tumorigenic factors (PubMed: 20577200). Therapeutic strategies targeting the MMP14 mRNA 3'-UTR involve the use of miRNA mimics or antisense oligonucleotides (ASOs) to restore regulatory control and reduce the proteolytic capacity of cancer cells. Understanding the structural and sequence motifs within this 3'-UTR is essential for developing precise RNA-targeted therapies that can mitigate the progression of aggressive malignancies. This target represents a significant focus in the field of epitranscriptomics and RNA-based drug discovery for oncology.
Targeting the 3'-UTR via complementary base pairing (e.g., by microRNAs or antisense oligonucleotides) leads to the recruitment of the RNA-induced silencing complex (RISC) or steric hindrance, resulting in mRNA degradation or translational inhibition of the MMP14 transcript (PubMed: 26066740).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Matrix metallopeptidase 14 mRNA 3'-untranslated region (MMP14 mRNA 3'-UTR).